Key Statments


Key statement on the emergency use authorisation and supply of the investigational antibody cocktail casirivimab and imdevimab in India.
On May 4, Roche India received an emergency use authorisation (EUA) for the investigational antibody cocktail casirivimab in India. This EUA was based on the data that have been filled for the EUA in the US and the CHMP scientific opinion in the European Union.;Read more.

Roche's statement on Tocilizumab (Actemra) supplies
We have observed an unprecedented demand for Tocilizumab (Brand: Actemra) given the significant increase in Covid cases across India in the last few weeks. Read more.

An Opportunity for India: Improving Transparency
The topic of clinical trial data transparency has attracted interest and debate around the globe. While some are wrestling with questions such as the ownership and management of genomic data, here in India, we are still addressing more fundamental questions. Questions continue to be asked as to whether or not data supporting regulatory decisions should be publicly available, and whether physicians are provided the information they need to make informed treatment decisions. Read more.

Providing confidence and support to patients
Roche India’s "The Blue Tree" program offers support to cancer patients during their treatment journey, from diagnosis till completion of therapy.It is a patient support initiative that is designed to take care of the multiple hurdles that a patient has to go through during the course of receiving treatment.  Read more

Approval of biosimilars must be subject to rigorous clinical and regulatory standards.
In order to ensure patients and physicians can make informed treatment decisions, it is critical that they have full access to information about products claiming to be similar to or a biosimilar of innovative biologics, and clarity on whether or not they have met the requirements for biosimilar products. Read more

Company Statement: Delhi High Court Interim Order, March 03, 2017